IL-6 Regulation of Substrate Metabolism and Influence of Obesity

• Status: Completed
• Trial end date: 2020-04-03
• Target enrollment: 0
• Participant gender: Male

Summary

The aim of the study is to investigate the effects of blocking IL-6 signaling with tocilizumab on lipid, glucose and protein metabolism during rest and exercise in healthy and obese humans.

Interleukin-6 is a molecule produced by a variety of cells and impacts on energy metabolism during fasting and fed conditions. Systemic IL-6 levels are low but increase acutely in response to fasting, exercise and infection, and also chronically in response to obesity and other conditions of lowgrade inflammation.Our recent human intervention study showed that IL-6 receptor blockade prevents exercise training from reducing visceral fat mass.

Whether IL-6 receptor blockade directly regulates lipolysis and/or lipid oxidation in humans is however unclear. Therefore, this study will be performed to investigate the physiological role of IL-6 on lipid, glucose and protein metabolism in humans.

• Phase: N/A
• Accepts Healthy Volunteers?: Accepts Healthy Volunteers

Details

• Lead Sponsor: Rigshospitalet, Denmark

Criteria

Inclusion Criteria:

• BMI < 18 and > 25 kg/m2 or ≥ 30 and ≤ 40 kg/m2

• Healthy (based on screening)

Exclusion Criteria:

• Smoking

• Severe thyroid or heart disease

• inflammatory diseases

• current infection

• liver disease

• kidney disease

• immunosuppressive disease

• corticosteroid use

• regular NSAID usage

• aspirin use >100 mg/d

• history of carcinoma

• history of tuberculosis

• anemia

• neutropenia

• low platelets

• bleeding disorders

• obstructive pulmonary disease